July 20, 2018 / 5:35 AM / Updated 2 hours ago
Roche gets breakthrough status for Alzheimer's test Elecsys
ZURICH (Reuters) - The U.S. Food and Drug Administration has granted Roche an accelerated review for its Elecsys product used to diagnose Alzheimer’s disease, the Swiss drugmaker said on Friday.
FILE PHOTO: The logo of Swiss pharmaceutical company Roche is pictured on the company's headquarters in Basel February 4, 2009. REUTERS/Christian Hartmann (SWITZERLAND)/File Photo
The FDA gave breakthrough device designation to Elecsys, which examines the cerebrospinal fluid in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease or other causes of dementia.
Reporting by John Revill; Editing by Amrutha Gayathri
Our Standards:The Thomson Reuters Trust Principles.
0 : 0
- narrow-browser-and-phone
- medium-browser-and-portrait-tablet
- landscape-tablet
- medium-wide-browser
- wide-browser-and-larger
- medium-browser-and-landscape-tablet
- medium-wide-browser-and-larger
- above-phone
- portrait-tablet-and-above
- above-portrait-tablet
- landscape-tablet-and-above
- landscape-tablet-and-medium-wide-browser
- portrait-tablet-and-below
- landscape-tablet-and-below